The World Intellectual Property Organization (WIPO) will host an Expert Forum on International Technology Transfer on 16 February 2015 to 18 February 2015 at its New Conference Hall. The event is open to the public, and the link for online registration can be found here: http://www.wipo.int/meetings/en/registration/form.jsp?meeting_id=35562.
(More KEI RCEP leaks here: /rcep)
Attached is a leaked version of Japan’s October 3, 2014 proposals for intellectual property for the Regional Comprehensive Economic Partnership.
Attached are KEI’s February 6 comments to USTR on the 2015 Special 301.
Our 7 page submission begins with this:
Attached are KEI’s January 30, 2015 comments on the India IP Policy.
/wp-content/uploads/KEI_30Jan2015_Comments_India_IPR_Policy.pdf
This is how the comments begin:
Knowledge Ecology International (KEI) has reviewed the document entitled “National IPR Policy” prepared by the IPR Think Tank. The document is surprisingly lacking in several key areas. In particular:
Today, on World Cancer Day, there has been many great announcements and celebrations.
The FDA approved Pfizer’s new drug Ibrance (INN: palbociclib) for the treatment of metastatic (advanced) breast cancer to be used in combination with letrozole based on a 165 person trial at UCLA’s cancer center. (FDA press release here, ABC story here.)
The first session of the 2015 World Trade Organization’s TRIPS Council takes place from 24 February 2015 to 25 February 2015. Like clockwork, the United States has tabled the inclusion of an additional item on Intellectual Property and Innovation. This marks the 8th time since November 2012 that the United States has submitted the inclusion of an additional agenda item to the TRIPS Council relating to intellectual property or innovation.
February 4, 2015 is World Cancer Day. The rapidly increasing cost of cancer drugs should be broadly discussed. The Union for Affordable Cancer Treatment (UACT), a union of people affected by cancer (http://cancerunion.org/) is asking the author and co-author of the “Tufts Cost Study,” –a not-yet-released “study” used to justify high prices of drugs without providing data– to address the following questions:
On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022. Continue Reading
Another matter considered during the Friday, January 30th session of the WHO Executive Board was the “Follow-up of the report on the Consultative Expert Working Group on Research Development-Financing and Coordination.” In addition to the general report on the CEWG, the EB also considered the Director General’s report on the CEWG “Health research and development demonstration projects.”
On Friday, January 30th, the WHO Executive Board discussed the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPA). The discussion covered several documents in relation to the GSPoA, including: